TRxADE HEALTH Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
TRxADE HEALTH (NASDAQ:MEDS) Third Quarter 2022 Results
Key Financial Results
Revenue: US$2.40m (down 5.9% from 3Q 2021).
Net loss: US$503.0k (loss narrowed by 61% from 3Q 2021).
US$0.061 loss per share (improved from US$0.16 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
TRxADE HEALTH EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 27%. Earnings per share (EPS) exceeded analyst estimates by 50%.
Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Online Retail industry in the US.
Performance of the American Online Retail industry.
The company's shares are down 13% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for TRxADE HEALTH (of which 2 are potentially serious!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
